Abstract
Background: COVID-19 has quickly become a global pandemic with a substantial number of deaths and is a considerable burden for healthcare systems worldwide. Although most cases are paucisymptomatic and limited to the viral infection-related symptoms, some patients evolve to a second phase, with an impaired inflammatory response (cytokine storm) that may lead to acute respiratory distress syndrome and death. This is thought to be caused by increased bradykinin synthesis.
Methods: ICAT-COVID is a multicenter, randomized, open-label, proof-of-concept phase II clinical trial assessing the clinical efficacy and safety of adding icatibant to the standard of care in patients hospitalized with COVID-19 without invasive mechanical ventilation. Patients hospitalized with a confirmed COVID-19 pneumonia diagnosis (RT-PCR or antigen test ≤ 10 days prior to randomization, and radiographic evidence of pulmonary infiltrates), rated “4” or “5” on the WHO’s clinical status scale, are eligible. Patients will be randomized on a 1:1 ratio to either standard of care-plus-icatibant (experimental group) or to standard of care alone (control group). The experimental group will receive 30 mg of icatibant subcutaneously 3 times a day for 3 days (for a total of 9 doses). The expected sample size is 120 patients (60 per group) from 2 sites in Spain. Primary outcomes are the efficacy and safety of Icatibant. The main efficacy outcome is the number of patients reaching grades “2” or “1” on the WHO scale within 10 days of starting treatment. Secondary outcomes include “long-term efficacy”: number of patients discharged who do not present COVID-19-related relapse or comorbidity up until 28 days after discharge, and mortality.
Discussion: Icatibant, a bradykinin type 2 receptor antagonist with proven effectiveness and safety against hereditary angioedema attacks, may be beneficial for COVID-19 patients by inhibiting bradykinin’s action on endothelial cells and by inhibiting the SARS-CoV-2 M protease. Our working hypothesis is that treatment with standard of care-plus-icatibant is effective and safe to treat patients infected with SARS-CoV-2 admitted to hospital for pneumonia without invasive mechanical ventilation.
Trial registration: EudraCT 2020-002166-13.
Clinicaltrials: gov NCT04978051 .
Keywords: ACE2; ARDS; Bradykinin; COVID-19; Icatibant; SARS; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, ACE2, ARDS, SARS, bradykinin, Icatibant, 【초록키워드】 Treatment, SARS-CoV-2, Respiratory distress syndrome, viral infection, Efficacy, ARDS, Cytokine storm, COVID-19 pneumonia, clinical trial, Hospitalized, Mortality, Open-label, randomization, acute respiratory distress syndrome, Pneumonia, hospital, Diagnosis, Comorbidity, protease, outcome, RT-PCR, Symptoms, discharge, Antigen, clinical status, global pandemic, Randomized, bradykinin, endothelial cells, Patient, Effectiveness, Spain, death, Icatibant, Efficacy and safety, receptor, multicenter, COVID-19 patients, acute respiratory distress, Endothelial cell, Evidence, Clinical efficacy, Invasive mechanical ventilation, Inflammatory response, COVID-19 patient, Healthcare system, Safe, evidence of, respiratory distress, receptor antagonist, Healthcare systems, Standard of care, Sample size, control group, Secondary outcomes, experimental group, Primary outcomes, syndrome, ClinicalTrials, EudraCT, treat, pulmonary infiltrates, Radiographic, doses, working hypothesis, attacks, effective, secondary, thought, caused, include, the WHO, expected, discharged, inhibiting, receive, 1:1, eligible, infected with SARS-CoV-2, patients hospitalized, subcutaneously, the SARS-CoV-2, with COVID-19, 【제목키워드】 clinical trial, Study protocol, hospital, Randomized, Patient, Icatibant, Efficacy and safety, infected with SARS-CoV-2, invasive mechanical,